Scientists Identify SARS-CoV-2 PLpro and RIPK1 Inhibitors Showing Potent Synergistic Antiviral Effects in Mouse COVID-19 Model

Why It Matters

Dual inhibition tackles both viral propagation and the cytokine storm, offering a strategy that could overcome resistance and improve outcomes for severe COVID‑19 patients.

Key Takeaways

• PLpro inhibitor SHY1643 blocks viral polyprotein processing.
• RIPK1 inhibitor QY1892 suppresses inflammatory signaling.
• Combined treatment dramatically lowers viral titers and cytokine levels.
• Dual targeting reduces lung pathology in SARS‑CoV‑2 mice.
• Host‑directed approach may limit antiviral resistance development.

Pulse Analysis

The COVID‑19 pandemic has exposed the limits of monotherapy antivirals that focus solely on viral polymerases or the spike protein. As SARS‑CoV‑2 continues to evolve, resistance and immune‑mediated pathology have become critical hurdles. Targeting the papain‑like protease (PLpro) offers a direct route to halt viral polyprotein cleavage while also restoring innate immune signaling, whereas inhibiting the host kinase RIPK1 can dampen the cytokine storm that drives severe disease. This dual‑focus strategy reflects a growing consensus that simultaneous viral and host modulation may yield more durable clinical outcomes.

In the recent Acta Pharmaceutica Sinica B paper, high‑throughput screening identified SHY1643 as a selective PLpro antagonist and QY1892 as a potent RIPK1 blocker. Both molecules displayed favorable pharmacokinetics and minimal off‑target activity in rodents. When administered together to SARS‑CoV‑2‑infected mice, the combination produced a synergistic reduction in viral load—exceeding 1‑log compared with monotherapy—and markedly suppressed IL‑6, TNF‑α, and other pro‑inflammatory mediators. Mechanistically, SHY1643 occupies the PLpro catalytic pocket, while QY1892 prevents RIPK1‑driven necroptosis, jointly curbing replication and tissue damage.

The preclinical success of SHY1643/QY1892 paves the way for a new class of combination antivirals that could be less vulnerable to viral escape mutations. By anchoring part of the therapeutic effect on a host target, the regimen may preserve efficacy across emerging variants and reduce selective pressure on the virus. Nonetheless, translation to humans will require rigorous safety profiling, dose‑optimization, and validation in diverse patient cohorts. If these hurdles are cleared, the PLpro‑RIPK1 paradigm could extend beyond COVID‑19, offering a template for treating other infections where viral replication and hyperinflammation intersect.